Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nautilus

Request full access

Delivering a high-throughput, low-cost platform for analyzing and quantifying the human proteome

Seattle, United StatesFounded 2016Biotech & Life Sciences

About Nautilus

Nautilus Biotechnology operates in the biotechnology sector, focusing on proteomics, which is the large-scale study of proteins. The company has developed an advanced platform designed to accelerate the drug development process by providing researchers with deep insights into the roles of drug targets in health and disease. This platform aims to make it easier to prioritize drug targets with high potential for clinical success, thereby reducing inefficiencies and costs associated with traditional drug discovery methods. Nautilus Biotechnology serves pharmaceutical companies, research institutions, and biotech firms, offering them a tool to enhance their research capabilities and improve clinical outcomes. The business model is primarily B2B (business-to-business), generating revenue through the sale of its proteomics platform and related services. By unlocking the proteome, Nautilus aims to fuel breakthroughs in basic biology, medicine, and biotechnology, ultimately impacting global health positively.

Source: Dealroom company data

At a glance

Status
Listed
Listing
Public via SPAC 2021

Nautilus in the Seattle ecosystem

Live from Dealroom

The Nautilus office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later7 investors entered at this stage

Employees mapped 150 incl. 3 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 9 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$17M

19 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Nautilus on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.